文献速递重症综合管理与镇静镇痛

帕博利珠单抗对比卡铂联合紫杉醇一线治疗错配修复缺陷晚期或复发性子宫内膜癌(KEYNOTE-C93/GOG-3064/ENGOT-en15):多中心、开放标签、随机、阳性对照3期试验中期分析

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.
PubMed 文献 · Lancet · 2026-10-26
一句话结论在错配修复缺陷晚期或复发性子宫内膜癌中,一线帕博利珠单抗较卡铂联合紫杉醇显著延长无进展生存期(中位38.2个月 vs 8.4个月,HR 0.57),总生存期未达预设显著性标准。

KEYNOTE-C93/GOG-3064/ENGOT-en15是一项在24个国家122个中心开展的多中心、开放标签、随机、阳性对照3期试验,纳入299例不可手术的III或IV期、持续、晚期或复发性错配修复缺陷子宫内膜癌成人患者,1:1随机接受帕博利珠单抗400 mg每6周静脉给药最多18周期,或卡铂(AUC 5或6 mg/mL/min)联合紫杉醇175 mg/m2每3周第1天给药共6周期。预设中期分析显示,帕博利珠单抗组中位无进展生存期38.2个月(95%CI 17.9个月-未达到)vs 卡铂联合紫杉醇组8.4个月(6.8-10.4),HR 0.57(95%CI 0.42-0.79;p=0.0002);总生存期未达预设显著性标准(中位数均未达到;HR 0.77,95%CI 0.52-1.15;p=0.10)。帕博利珠单抗组3级及以上治疗相关不良事件18%(27/149)vs 卡铂联合紫杉醇组51%(73/144)。作者指出该研究未比较帕博利珠单抗单药与当前标准治疗(免疫治疗联合化疗)。

要点

  • dMMR晚期或复发性子宫内膜癌一线帕博利珠单抗组中位无进展生存期38.2个月(95%CI 17.9-未达到)vs 卡铂联合紫杉醇组8.4个月(6.8-10.4),HR 0.57(95%CI 0.42-0.79;p=0.0002)。
  • 帕博利珠单抗组12个月无进展生存率67%(95%CI 59-74)vs 卡铂联合紫杉醇组40%(32-48);36个月分别为53%(44-61)vs 30%(22-38)。
  • 总生存期中期分析未达预设显著性标准:两组中位均未达到,HR 0.77(95%CI 0.52-1.15;p=0.10)。
  • 3级及以上治疗相关不良事件帕博利珠单抗组18%(27/149)vs 卡铂联合紫杉醇组51%(73/144);治疗相关不良事件致停药分别为9%(14/149)vs 15%(21/144)。
  • 作者指出本研究未比较帕博利珠单抗单药与当前标准治疗(免疫治疗联合化疗)。

适用人群与场景

  • 成人(≥18岁)不可手术的III或IV期、持续、晚期或复发性错配修复缺陷(dMMR)子宫内膜癌患者。
  • 研究在美洲、亚洲、欧洲和大洋洲24个国家122个中心开展。

诊断标准与关键阈值

  • 错配修复缺陷(dMMR)晚期或复发性子宫内膜癌。
  • 不可手术的III期或IV期、持续、晚期或复发性疾病。

处置流程与药物剂量

  • 帕博利珠单抗400 mg静脉给药,每6周一次,最多18个周期。
  • 卡铂按曲线下面积(AUC)5 mg/mL/min或6 mg/mL/min联合紫杉醇175 mg/m2静脉给药,每3周周期第1天,共6个周期。
  • 随机化按疾病状态、组织学和既往是否接受(新)辅助化疗分层。

红旗征与不能漏的情况

  • 帕博利珠单抗组治疗相关不良事件导致死亡2例(肝功能衰竭和细菌性脑膜炎各1例)。
  • 卡铂联合紫杉醇组治疗相关不良事件导致死亡1例(肺栓塞)。

研究设计与关键结果

  • 多中心、开放标签、随机、阳性对照3期试验,299例受试者随机分配至帕博利珠单抗组(n=149)或卡铂联合紫杉醇组(n=150)。
  • 主要终点为盲法独立中心评审按RECIST 1.1评估的无进展生存期和总生存期。
  • 预设中期分析(数据截止2026年4月24日,意向治疗人群)中位无进展生存期:帕博利珠单抗组38.2个月(95%CI 17.9个月-未达到)vs 卡铂联合紫杉醇组8.4个月(6.8-10.4),HR 0.57(95%CI 0.42-0.79;p=0.0002)。
  • 估计无进展生存率:6个月时帕博利珠单抗组75%(95%CI 67-81)vs 卡铂联合紫杉醇组76%(68-82);12个月时67%(59-74)vs 40%(32-48);36个月时53%(44-61)vs 30%(22-38)。
  • 总生存期预设统计显著性标准未达到:两组中位均未达到,HR 0.77(95%CI 0.52-1.15;p=0.10)。
  • 3级及以上治疗相关不良事件:帕博利珠单抗组27/149(18%)vs 卡铂联合紫杉醇组73/144(51%)。
  • 任一组发生率≥25%的任何级别治疗相关不良事件:脱发帕博利珠单抗组3/149(2%)vs 卡铂联合紫杉醇组72/144(50%);贫血7/149(5%)vs 71/144(49%);恶心7/149(5%)vs 41/144(28%);中性粒细胞计数降低5/149(3%)vs 40/144(28%);周围神经病帕博利珠单抗组无 vs 38/144(26%);疲乏20/149(13%)vs 37/144(26%)。
  • 治疗相关不良事件导致停药:帕博利珠单抗组14/149(9%)vs 卡铂联合紫杉醇组21/144(15%)。

证据类型、等级与局限

  • 证据类型:多中心、开放标签、随机、阳性对照3期试验的中期分析。
  • 作者指出本研究未比较帕博利珠单抗单药与当前标准治疗(免疫治疗联合化疗)。

对床旁实践的改变

  • 在dMMR晚期或复发性子宫内膜癌一线治疗中,帕博利珠单抗较卡铂联合紫杉醇显著改善无进展生存期且不良事件频率更低;总生存期中期分析未达预设显著性标准,研究未比较帕博利珠单抗单药与免疫治疗联合化疗这一当前标准治疗。

指南或共识出处

  • KEYNOTE-C93/GOG-3064/ENGOT-en15(ClinicalTrials.gov NCT05173987),由默克夏普与多姆公司(Merck Sharp & Dohme,默克公司的子公司)资助。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: A need exists for first-line chemotherapy-free options in advanced or recurrent endometrial cancer. We therefore assessed the efficacy, quality of life, and safety of first-line pembrolizumab versus carboplatin plus paclitaxel in mismatch repair-deficient (dMMR) advanced or recurrent endometrial cancer.

METHODS: The KEYNOTE-C93/GOG-3064/ENGOT-en15 multicentre, open-label, randomised, active-comparator controlled, phase 3 trial was conducted at 122 centres in 24 countries in the Americas, Asia, Europe, and Oceania. Adult participants (≥18 years) with inoperable, stage III or IV, persistent, advanced, or recurrent dMMR endometrial cancer were randomly assigned 1:1 to intravenous pembrolizumab 400 mg every 6 weeks for up to 18 cycles or intravenous carboplatin area under the curve 5 mg/mL or 6 mg/mL per min plus paclitaxel 175 mg/m2 on day 1 of each 3-week cycle for six cycles. Randomisation was stratified by disease status, histology, and previous receipt of (neo)adjuvant chemotherapy. Primary endpoints were progression-free survival per RECIST version 1.1, by blinded independent central review, and overall survival. This trial is registered at ClinicalTrials.gov, NCT05173987, and is ongoing.

FINDINGS: Between Feb 22, 2022, and Dec 12, 2023, 299 participants were assigned to pembrolizumab (n=149) or carboplatin plus paclitaxel (n=150). At the cutoff for the prespecified interim analysis in the intention-to-treat population (April 24, 2026), median progression-free survival was 38·2 months (95% CI 17·9 months-not reached) in the pembrolizumab group versus 8·4 months (6·8-10·4) in the carboplatin plus paclitaxel group (hazard ratio [HR] 0·57, 95% CI 0·42-0·79; p=0·0002). Estimated progression-free survival was 75% (95% CI 67-81) versus 76% (68-82) at 6 months, 67% (59-74) versus 40% (32-48) at 12 months, and 53% (44-61) versus 30% (22-38) at 36 months. The prespecified statistical significance criterion for overall survival was not met at the interim analysis (medians not reached; HR 0·77, 95% CI 0·52-1·15; p=0·10). Grade 3 or higher treatment-related adverse events occurred in 27 (18%) of 149 participants in the pembrolizumab group and 73 (51%) of 144 in the carboplatin plus paclitaxel group. Treatment-related adverse events of any grade that occurred in at least 25% of participants in either group included alopecia (three [2%] of 149 in the pembrolizumab group, 72 [50%] of 144 in the carboplatin plus paclitaxel group), anaemia (seven [5%], 71 [49%]), nausea (seven [5%], 41 [28%]), decreased neutrophil count (five [3%], 40 [28%]), peripheral neuropathy (none, 38 [26%]), and fatigue (20 [13%], 37 [26%]). Treatment-related adverse events led to treatment discontinuation in 14 (9%) of 149 participants in the pembrolizumab group and 21 (15%) of 144 participants in the carboplatin plus paclitaxel group; they resulted in death in two participants in the pembrolizumab group (hepatic failure and bacterial meningitis [n=1 each]) and one participant in the carboplatin plus paclitaxel group (pulmonary embolism).

INTERPRETATION: First-line pembrolizumab showed a statistically significant and clinically meaningful improvement in progression-free survival, with lower frequency of overall and grade 3 or above treatment-related adverse events. The study did not compare pembrolizumab monotherapy with the current standard of care (immunotherapy plus chemotherapy).

FUNDING: Merck Sharp & Dohme, a subsidiary of Merck & Co.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Slomovitz, Zhu, Yin, et al. First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial. Lancet. 2026. PMID: 42933458. doi:10.1016/S0140-6736(26)02095-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。